journal article·2025-03-10Open access

RETRACTED: Fabrication of Oro-Dispersible Sodium Valproate-Loaded Nanofibrous Patches for Immediate Epileptic Innervation

Ece Guler, Humeyra B. Yekeler, Zarife N. Ozdemir Kumral, Gita Parviz, Gul S. Ozcan, Burcu Uner, Sinem G. Demirbas, Simge Ayyildiz, Yusufhan Yazir, Deepak Kalaskar, Muhammet E. Cam

This record is marked as retracted by the source. Review the publisher’s notice before using its findings.

Abstract

High Resolution Image Download MS PowerPoint Slide Epilepsy is one of the oldest neurological disorders discovered by mankind. This condition is firmly coupled with unprovoked seizures stimulated by irrepressible neuroelectrical blasts. Orally taken valproate family has been employed for prophylactic management; however, oral administration is not applicable for critical scenarios, thus calling for medication routes fulfilling necessities of immediate innervation. In order to address this shortcoming, sodium valproate entrapped in poly(ethylene oxide)/polyvinylpyrrolidone (PEO/PVP) nanofibrous patches was developed with the aim of sublingual drug delivery. Initially, the production process was designed and optimized via the central composite design (CCD). Nanofiber fabrication was accomplished with a novel device by using the pressurized gyration method. Fabricated biomaterials were chemically, spatially, and thermally inspected. The beanless and homogeneous appearance of both virgin and impregnated nanofibrous patches was morphologically demonstrated via scanning electron microscopy. Additionally, adequately oro-dispersed impregnated patches released more than 90% of their drug content in under a minute. Following in vitro cyto-safety assurance acquired through 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay on SH-SY5Y neuroblastoma cells, the protective antiepileptic effect of impregnated patches was affirmed in vivo via pentylenetetrazole kindled-induced Mus musculus animal modeling. The parameter of in vivo behavioral evaluation was the Racine scoring system. Moreover, histopathological distinctions detected between different test groups were highlighted via fluorescence staining. Finally, the oxidative stress was determined according to quantitative variations of malondialdehyde, glutathione, superoxide dismutase, and catalase levels. The overall conclusion herein suggests that sodium valproate-loaded PEO/PVP nanofibrous patches strikingly prevented behavioral, structural, and oxidative deteriorations caused by pentylenetetrazole.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Graphene and Nanomaterials Applications · Neuroscience and Neural Engineering · Electrospun Nanofibers in Biomedical Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmacology, Faculty of Pharmacy

Istanbul Kent University

Center for Nanotechnology and Biomaterials Application and Research

Marmara University

Division of Surgery and Interventional Sciences

University College London

MecNano Technologies, Cube Incibation, Teknopark Istanbul, Istanbul 34906, Türkiye

Department of Physiology, Faculty of Medicine

Stem Cell and Gene Therapies Research and Applied Center, Medical Faculty

Kocaeli University

Department of Pharmaceutical and Administrative Sciences

University of Health Science and Pharmacy in St. Louis

Department of Anesthesiology, Center for Clinical Pharmacology, School of Medicine

Washington University

Department of Pharmaceutical Technology, Faculty of Pharmacy

Funding

T?rkiye Bilimsel ve Teknolojik Arastirma Kurumu

References (71)

Show source-provided references
1. 10.1016/j.arabjc.2020.10.03410.1016/j.arabjc.2020.10.034 ↗
2. 10.1055/s-0040-171871910.1055/s-0040-1718719 ↗
3. 10.1038/nn.394710.1038/nn.3947 ↗
4. 10.3928/00904481-20150203-1010.3928/00904481-20150203-10 ↗
5. 10.1111/j.1528-1167.2005.463007.x10.1111/j.1528-1167.2005.463007.x ↗
6. 10.2165/00023210-200115050-0000110.2165/00023210-200115050-00001 ↗
7. 10.1016/j.eplepsyres.2019.10621910.1016/j.eplepsyres.2019.106219 ↗
8. Nolan, S. J.; Marson, A. G.; Pulman, J.; Tudur Smith, C. Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures Cochrane Database Syst. Rev. 2013CD001769 10.1002/14651858.CD001769.pub2.10.1002/14651858.CD001769.pub2 ↗
9. 10.1016/j.pediatrneurol.2013.10.00910.1016/j.pediatrneurol.2013.10.009 ↗
10. Alsarra I. A. · 2005 · 32
11. 10.1080/00207454.2020.173296710.1080/00207454.2020.1732967 ↗
12. 10.1016/j.yebeh.2023.10929410.1016/j.yebeh.2023.109294 ↗
13. 10.1016/j.carpta.2021.10003510.1016/j.carpta.2021.100035 ↗
14. 10.3109/21691401.2015.105247210.3109/21691401.2015.1052472 ↗
15. 10.1016/j.jddst.2020.10172610.1016/j.jddst.2020.101726 ↗
16. 10.1080/10837450.2019.161508810.1080/10837450.2019.1615088 ↗
17. 10.3109/10837450.2014.100365510.3109/10837450.2014.1003655 ↗
18. 10.1016/j.ijpharm.2024.12423010.1016/j.ijpharm.2024.124230 ↗
19. 10.2174/156720181566618072311560010.2174/1567201815666180723115600 ↗
20. 10.3389/fbioe.2023.124432310.3389/fbioe.2023.1244323 ↗
21. 10.1016/j.jddst.2017.11.00810.1016/j.jddst.2017.11.008 ↗
22. 10.1016/j.mtchem.2020.10041610.1016/j.mtchem.2020.100416 ↗
23. 10.3109/03639045.2015.113593910.3109/03639045.2015.1135939 ↗
24. Information, N. C. f. B. PubChem. Compound Summary for CID 16760703, Valproate Sodium, 2024.
25. 10.1039/c2jm31069d10.1039/c2jm31069d ↗
26. 10.1002/mabi.20180025610.1002/mabi.201800256 ↗
27. Alenezi, H.; Cam, M. E.; Edirisinghe, M. Core–sheath polymer nanofiber formation by the simultaneous application of rotation and pressure in a novel purpose-designed vessel Appl. Phys. Rev. 2021; Vol. 8 410.1063/5.0071257.10.1063/5.0071257 ↗
28. Pytko-Polonczyk J. · J. Physiol. Pharmacol. · 2017 · 68 · 807
29. 10.1016/j.ijbiomac.2022.02.03010.1016/j.ijbiomac.2022.02.030 ↗
30. 10.1016/j.ijbiomac.2017.02.09810.1016/j.ijbiomac.2017.02.098 ↗
31. 10.1021/acs.molpharmaceut.1c0068910.1021/acs.molpharmaceut.1c00689 ↗
32. 10.1016/S0378-5173(02)00545-810.1016/S0378-5173(02)00545-8 ↗
33. 10.1016/j.ejmech.2016.08.00710.1016/j.ejmech.2016.08.007 ↗
34. 10.1021/acsomega.2c0342810.1021/acsomega.2c03428 ↗
35. 10.1007/s00210-016-1220-z10.1007/s00210-016-1220-z ↗
36. 10.1155/2014/51268210.1155/2014/512682 ↗
37. 10.1093/ndt/gfac05310.1093/ndt/gfac053 ↗
38. Kumral Z. N. · J. Physiol. Pharmacol. · 2016 · 67 · 45
39. 10.1016/j.ajps.2017.12.00610.1016/j.ajps.2017.12.006 ↗
40. 10.1016/j.ijbiomac.2023.12863510.1016/j.ijbiomac.2023.128635 ↗
41. 10.1007/s10965-022-03011-810.1007/s10965-022-03011-8 ↗
42. 10.1016/j.matpr.2016.11.01810.1016/j.matpr.2016.11.018 ↗
43. 10.3390/molecules2409178510.3390/molecules24091785 ↗
44. 10.1016/j.jmrt.2017.06.00910.1016/j.jmrt.2017.06.009 ↗
45. 10.1016/j.ijbiomac.2020.06.26510.1016/j.ijbiomac.2020.06.265 ↗
46. 10.1016/j.jcou.2022.10215910.1016/j.jcou.2022.102159 ↗
47. 10.3390/ma1313297910.3390/ma13132979 ↗
48. 10.1208/s12249-008-9048-610.1208/s12249-008-9048-6 ↗
49. 10.1016/j.scriptamat.2004.05.00710.1016/j.scriptamat.2004.05.007 ↗
50. 10.1002/cmdc.20080011210.1002/cmdc.200800112 ↗
51. 10.3390/pharmaceutics1209086610.3390/pharmaceutics12090866 ↗
52. 10.1002/app.4640310.1002/app.46403 ↗
53. 10.1039/D2CP05972J10.1039/D2CP05972J ↗
54. 10.1016/S0378-5173(01)00613-510.1016/S0378-5173(01)00613-5 ↗
55. 10.1016/j.ejpb.2011.02.01410.1016/j.ejpb.2011.02.014 ↗
56. 10.18579/jpcrkc/2017/16/3/11876610.18579/jpcrkc/2017/16/3/118766 ↗
57. 10.3390/polym1407129910.3390/polym14071299 ↗
58. 10.1016/0142-9612(93)90215-N10.1016/0142-9612(93)90215-N ↗
59. 10.1016/j.jddst.2023.10489310.1016/j.jddst.2023.104893 ↗
60. 10.37385/msej.v4i6.367210.37385/msej.v4i6.3672 ↗
61. Campos J. R. · 2020 · 45710.1201/9780429399039-16 ↗
62. 10.3389/fphar.2015.0028610.3389/fphar.2015.00286 ↗
63. 10.1016/j.lwt.2020.10998410.1016/j.lwt.2020.109984 ↗
64. 10.1016/j.lfs.2020.11808110.1016/j.lfs.2020.118081 ↗
65. Shakya A. K. · 2018 · 25910.1016/B978-0-12-814423-7.00008-3 ↗
66. Jampílek J. · 2019 · 15110.1201/9781351137263-5 ↗
67. 10.1002/jcb.2442210.1002/jcb.24422 ↗
68. 10.1016/j.ejps.2018.05.02610.1016/j.ejps.2018.05.026 ↗
69. 10.1016/j.polymer.2008.09.04110.1016/j.polymer.2008.09.041 ↗
70. 10.3109/1052029910910999010.3109/10520299109109990 ↗
71. 10.1016/S0006-3223(00)00878-710.1016/S0006-3223(00)00878-7 ↗